

CCR Translations

- Estrogen Receptor–Negative Breast Cancer: New Insights into Subclassification and Targeting.** Jean J. Zhao and Daniel P. Silver6309
 Commentary on Speers et al., p. 6327
- Trastuzumab: A Picky Partner?** Heather L. McArthur and Clifford A. Hudis6311
 Commentary on Francia et al., p. 6358

Molecular Pathways

- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair.** Emma Bolderson, Derek J. Richard, Bin-Bing S. Zhou, and Kum Kum Khanna6314
- Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure.** Rihab Nasr, Valérie Lallemand-Breitenbach, Jun Zhu, Marie-Claude Guillemin, and Hugues de Thé6321

Human Cancer Biology

- Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer.** Corey Speers, Anna Tsimelzon, Krystal Sexton, Ashley M. Herrick, Carolina Gutierrez, Aedin Culhane, John Quackenbush, Susan Hilsenbeck, Jenny Chang, and Powel Brown6327
- Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma.** Rezaul Karim, Ekaterina S. Jordanova, Sytse J. Piersma, Gemma G. Kenter, Lieping Chen, Judith M. Boer, Cornelis J. M. Melief, and Sjoerd H. van der Burg6341
- Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer.** Magis Mandapathil, Miroslaw J. Szczepanski, Marta Szajnik, Jin Ren, Diana E. Lenzner, Edwin K. Jackson, Elieser Gorelik, Stephan Lang, Jonas T. Johnson, and Theresa L. Whiteside6348

Cancer Therapy: Preclinical

- Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts.** Giulio Francia, Shan Man, Chyan-Jang Lee, Christina R. Lee, Ping Xu, Miriam E. Mossoba, Urban Emmenegger, Jeffrey A. Medin, and Robert S. Kerbel6358
- Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity.** Davide Melisi, Valeria Ossovskaia, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese, and Paul J. Chiao6367

Imaging, Diagnosis, Prognosis

- Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients.** Zoran Erlic, Lisa Rybicki, Mariola Peczkowska, Henriette Golcher, Peter H. Kann, Michael Brauckhoff, Karsten Müssig, Michaela Muresan, Andreas Schäffler, Nicole Reisch, Matthias Schott, Martin Fassnacht, Giuseppe Opocher, Silke Klose, Christian Fottner, Flavio Forrer, Ursula Plöckinger, Stephan Petersenn, Dimitry Zabolotny, Oleg Kollukch, Svetlana Yaremchuk, Andrzej Januszewicz, Martin K. Walz, Charis Eng, and Hartmut P.H. Neumann for the European-American Pheochromocytoma Study Group6378

An Embryonic Stem Cell–Like Signature Identifies Poorly Differentiated Lung Adenocarcinoma but not Squamous Cell Carcinoma. Khaled A. Hassan, Guoan Chen, Gregory P. Kalemkerian, Max S. Wicha, and David G. Beer	6386
Gender Disparities in Metastatic Colorectal Cancer Survival. Andrew Hendifar, Dongyun Yang, Felicitas Lenz, Georg Lurje, Alexandra Pohl, Cosima Lenz, Yan Ning, Wu Zhang, and Heinz-Josef Lenz.....	6391
Overexpression of Prostate-Specific <i>TMPRSS2(exon 0)</i>-<i>ERG</i> Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer. Karin G. Hermans, Joost L. Boormans, Delila Gasi, Geert J.H.L. van Leenders, Guido Jenster, Paul C.M.S. Verhagen, and Jan Trapman	6398
Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma. Hanyang Lin, Ronald P.C. Wong, Magdalena Martinka, and Gang Li	6404
Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. Shuji Ogino, Katsuhiko Noshio, Natsumi Irahara, Jeffrey A. Meyerhardt, Yoshifumi Baba, Kaori Shima, Jonathan N. Glickman, Cristina R. Ferrone, Mari Mino-Kenudson, Noriko Tanaka, Glenn Dranoff, Edward L. Giovannucci, and Charles S. Fuchs	6412
Recombinant Peptides as Biomarkers for Tumor Response to Molecular Targeted Therapy. Ralph J. Passarella, Li Zhou, John G. Phillips, Hongmei Wu, Dennis E. Hallahan, and Roberto Diaz	6421
Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Matija Snuderl, April F. Eichler, Keith L. Ligon, Quynh U. Vu, Michael Silver, Rebecca A. Betensky, Azra H. Ligon, Patrick Y. Wen, David N. Louis, and A. John Iafrate	6430
DNA Ploidy Cytometry Testing for Cervical Cancer Screening in China (DNACIC Trial): a Prospective Randomized, Controlled Trial. Hua Tong, Rong Shen, ZhuMing Wang, YanJing Kan, YiQuan Wang, FengShan Li, FuZhou Wang, Jie Yang, and XiRong Guo for the Mass Cervical Cancer Screening Regimen Group (MACREG).....	6438

Cancer Therapy: Clinical


Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma. Stephen M. Ansell, Sara A. Hurvitz, Patricia A. Koenig, Betsy R. LaPlant, Brian F. Kabat, Donna Fernando, Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, and John M. Timmerman.....	6446
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. Evangelos Briasoulis, Periklis Pappas, Christian Puozzo, Christos Tolis, George Fountzilas, Urania Dafni, Marios Marselos, and Nicholas Pavlidis	6454
The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [⁹⁰Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial. Andrew M. Evens, William G. Spies, Irene B. Helenowski, David Patton, Stewart Spies, Boriko D. Jovanovic, Sarah Miyata, Elizabeth Hamilton, Daina Variakojis, Jun Chen, Louie Naumovski, Steven T. Rosen, Jane N. Winter, Richard A. Miller, and Leo I. Gordon.....	6462

Correction

Correction: A Three-Gene Signature for Outcome in Soft Tissue Sarcoma	6472
--	------

About the Cover

APL is driven by a PML/RARA fusion that enhances self-renewal of clonogenic progenitors and blocks promyelocytes differentiation. PML/RARA binds RXR, Daxx and corepressors. Retinoic acid promotes differentiation through transcriptional activation and PML/RARA degradation by the proteasome. Arsenic primarily degrades PML/RARA, through sumoylation of its PML moiety and subsequent ubiquitination. Oncogene degradation affects self-renewal of the progenitors and tightly correlates with disease clearance and cure. For further details, please see Nasr and coworkers on page 6321 in this issue.



Clinical Cancer Research

15 (20)

Clin Cancer Res 2009;15:6309-6472.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/15/20>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/15/20>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.